Avid Bioservices Acquired by GHO and Ampersand Capital

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Avid Bioservices ( (CDMO) ) just unveiled an announcement.

On February 5, 2025, Avid Bioservices completed its acquisition by GHO Capital and Ampersand Capital Partners, a transaction valued at approximately $1.1 billion. This acquisition, which led to the delisting of Avid’s stock from Nasdaq, is expected to support Avid’s rapid growth, expand its service offerings, and enhance its capabilities with the backing of GHO and Ampersand’s expertise in healthcare investments, particularly in the CDMO sector. The merger signifies a strategic move to accelerate innovation and expand Avid’s market reach globally, benefiting stakeholders by potentially increasing the company’s growth and market positioning.

More about Avid Bioservices

Avid Bioservices is a dedicated Contract Development and Manufacturing Organization (CDMO) focused on the development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries, with more than 30 years of experience in producing biologics.

YTD Price Performance: 1.38%

Average Trading Volume: 2,256,868

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $798.9M

Find detailed analytics on CDMO stock on TipRanks’ Stock Analysis page.